The short version of HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-11. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Brachytherapy is used to place a sealed radioactive source inside or near the body to treat cancer, such as prostate cancer. Afterloading brachytherapy is often combined with teletherapy, which is external radiation delivered from a greater distance than brachytherapy. It is not classified as a nuclear medicine procedure, although like nuclear medicine, it uses the radiation emitted by radionuclides. After initial interest in brachytherapy in the early 20th century, its use declined in the mid-20th century because of the radiation exposure to physicians from manual handling of the radiation sources. It was not until the development of remote-controlled afterloading systems and the use of new radiation sources in the 1950s and 1960s that the risk of unnecessary radiation exposure to physicians and patients was reduced. In the afterloading procedure, an empty, tubular applicator is inserted into the target volume (e.g., the uterus) before the actual therapy and, after checking the position, loaded with a radioactive preparation. The preparation is located at the tip of a steel wire that is advanced and retracted step by step under computer control. After the pre-calculated time, the source is withdrawn into a safe and the applicator is removed. The procedure is used for breast cancer, bronchial carcinoma or oral floor carcinoma, among others. Beta emitters such as 90Sr or 106Ru or 192Ir are used.
Significant efforts in the mid-20th century helped clarify its nomenclature, stabilising its current name. Although there were challenges to this name in the 1980s, it was confirmed as valid in 2004. More recently, DNA studies suggest that there may be hidden diversity within the species, indicating the need for further taxonomic evaluation. The lichen is used as a spice in Indian cuisine. For this purpose, it is commonly known as black stone flower or kalpasi (among other names). Although nearly tasteless on its own, it releases an earthy fragrance and taste when cooked in with oil or butter.
Norgestrienone, sold under the brand names Ogyline, Planor, and Miniplanor, is a progestin medication which has been used in birth control pills, sometimes in combination with ethinylestradiol. It was developed by Roussel Uclaf and has been registered for use only in France. Under the brand name Planor, it has been marketed in France as 2 mg norgestrienone and 50 μg ethinylestradiol tablets. It is taken by mouth. Norgestrienone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has some androgenic activity. Norgestrienone was first described in the literature in 1965. It is sometimes referred to as a "second-generation" progestin. Norgestrienone is no longer available.
=== June === 21 June – Ahead of the unfolding secret payment scandal, the Director General of RTÉ, Dee Forbes, was suspended from her employment by the RTÉ Board, and later issued a statement defending her record. 22 June The postal service An Post moved from its historic headquarters in the General Post Office building on O'Connell Street in Dublin to new premises at North Wall Quay. RTÉ admitted that it paid its top presenter Ryan Tubridy €345,000 more than publicly declared between 2017 and 2022, in what the chair of its board said was a "serious breach of trust with the public". 24 June – All 30 remaining Argos retail stores in Ireland closed permanently. 25 June – Phase 5a of the BusConnects transport infrastructure programme was launched in Dublin 26 June – Dee Forbes resigned as Director-General of RTÉ with immediate effect, following ongoing controversy over undisclosed payments to broadcaster Ryan Tubridy.
Sources: en.wikipedia.org
Septoplasty is a corrective surgical procedure for nasal septum deviation in which the nasal septum is straightened. Tonsillectomy or adenoidectomy in an attempt to increase the size of the airway. Tonsillotomy Removal or reduction of parts of the soft palate and some or all of the uvula, such as uvulopalatopharyngoplasty (UPPP) or laser-assisted uvulopalatoplasty (LAUP). Modern variants of this procedure sometimes use radiofrequency waves to heat and remove tissue. Turbinectomy is a surgical procedure in which all or some of the turbinate bones are removed to relieve nasal obstruction. Reduction of the tongue base, either with laser excision or radiofrequency ablation. Genioglossus advancement, in which a small portion of the lower jaw that attaches to the tongue is moved forward, to pull the tongue away from the back of the airway. Hyoid suspension, in which the hyoid bone in the neck, another attachment point for tongue muscles, is pulled forward in front of the larynx. Maxillomandibular advancement Bariatric surgery (for morbid obesity) Hypoglossal nerve stimulation Radiofrequency ablation
== Classification == The term nevus is applied to a number of conditions caused by neoplasias and hyperplasias of melanocytes, as well as a number of pigmentation disorders, both hypermelanotic (containing increased melanin, the pigment responsible for skin color) and hypomelanotic (containing decreased melanin). Suspicious skin moles which are multi-colored or pink may be a finding in skin cancer.
== Treatment == CTD is difficult to treat because the transporter responsible for transporting creatine to the brain and muscles is defective. Affected individuals have sufficient amounts of creatine, but it cannot get to the tissues where it is needed. Studies in which oral creatine monohydrate supplements were given to patients with CTD found that patients did not respond to treatment. Patients with CTD are unresponsive to oral creatine monohydrate supplements because regardless of the amount of creatine they ingest, the creatine transporter is still defective, and therefore creatine is incapable of being transported across the BBB. Therapeutic approaches that are currently in development include dodecyl creatine ester (DCE) for intranasal creatine delivery, pharmacochaperones to aid in rescuing misfolded transporter, and gene therapy to compensate for the mutated SLC6A8 gene.
[The French] had agreed to a Jewish National Home, not a Jewish State. They considered we were steering straight upon the latter, and the very last thing they would do was to enlarge that State for they totally disapproved our policy. Greece's Foreign Minister told the editor of the Salonica Jewish organ Pro-Israel that "the establishment of a Jewish State meets in Greece with full and sincere sympathy ... A Jewish Palestine would become an ally of Greece." In Switzerland, a number of noted historians including professors Tobler, Forel-Yvorne, and Rogaz, supported the idea of establishing a Jewish state, with one referring to it as "a sacred right of the Jews." While in Germany, officials and most of the press took the Declaration to mean a British sponsored state for the Jews. The British government, including Churchill, made it clear that the Declaration did not intend for the whole of Palestine to be converted into a Jewish National Home, "but that such a Home should be founded in Palestine." Emir Faisal, King of Syria and Iraq, made a formal written agreement with Zionist leader Chaim Weizmann, which was drafted by T. E. Lawrence, whereby they would try to establish a peaceful relationship between Arabs and Jews in Palestine. The 3 January 1919 Faisal–Weizmann Agreement was a short-lived agreement for Arab–Jewish cooperation on the development of a Jewish homeland in Palestine.
=== Spelling and etymology === Sulfur is derived from the Latin word sulpur, which was Hellenized to sulphur in the erroneous belief that the Latin word came from Greek. This spelling was later reinterpreted as representing an /f/ sound and resulted in the spelling sulfur, which appears in Latin toward the end of the Classical period. The Ancient Greek word for sulfur, θεῖον, theîon (from earlier θέειον, théeion), is the source of the international chemical prefix thio-. In 12th-century Anglo-French, it was sulfre. In the 14th century, the erroneously Hellenized Latin -ph- was restored in Middle English sulphre. By the 15th century, both full Latin spelling variants sulfur and sulphur became common in English. The parallel f~ph spellings continued in Britain until the 19th century, when the word was standardized as sulphur. In the U.S., Webster's Dictionary (1828) lists only sulphur, and sulfur only becomes the primary entry in 1961. Nonetheless, the form sulfur was widely adopted in the United States during the 19th century. Canada uses both spellings. The IUPAC adopted the spelling sulfur in 1990. UK institutions soon followed: the Royal Society of Chemistry in 1992; the British Standards Institute in 1993; the UK national school curriculum in 2000 (there was some controversy). It is now the more common spelling in British books. The World Health Organization has mandated sulfur since at least 1993. The 1989 edition of the Oxford English Dictionary gave sulphur as the headword, and listed sulfur as a U.S.
Sources: en.wikipedia.org
== Further reading == Alberts, B. et al. (2002). Molecular Biology of the Cell, 4th ed. New York: Garland Science. ISBN 0-8153-3218-1. Berg, J. M. et al. (2002). Biochemistry, 5th ed. New York: W.H. Freeman and Company. ISBN 0-7167-3051-0. Singh, B. D. (2002). Fundamentals of Genetics, New Delhi, India: Kalyani Publishers. ISBN 81-7663-109-4.
Lipohypertrophy is a lump under the skin caused by accumulation of extra fat at the site of many subcutaneous injections of insulin. It may be unsightly, mildly painful, and may change the timing or completeness of insulin action. It is a common, minor, chronic complication of diabetes mellitus. Typical injection site hypertrophy is several inches or centimeters across, smoothly rounded, and somewhat firmer than ordinary subcutaneous fat. There may be some scar tissue as well, but the major component is adipose tissue, as insulin exerts a hypertrophic effect on adipose cells. To avoid lipohypertrophy, persons with diabetes mellitus who inject insulin daily for an extended period of time are advised to rotate their injections among several areas (usually upper, outer arms, outer thighs, abdomen below and around the umbilicus, and the upper parts of the buttocks). Rotation charts are often provided as part of diabetes education to help prevent lipohypertrophy. Lipohypertrophy usually will gradually disappear over months if injections in the area are avoided. It is a common misconception that the lump is largely scar tissue, as injection site hypertrophy is much rarer and milder with injections of other hormones and medications which lack the specific ability of insulin to stimulate adipose hypertrophy. In a sense, the "opposite" of injection site lipohypertrophy is injection site lipoatrophy, in which the subcutaneous fat around an injected area "melts away" over a few weeks or months, leaving unsightly, well-demarcated depressions in the skin.
Centromere protein A, also known as CENPA, is a protein which in humans is encoded by the CENPA gene. CENPA is a histone H3 variant which is the critical factor determining the kinetochore position(s) on each chromosome in most eukaryotes including humans.
== Nutrition == Red meat contains large amounts of iron, creatine, minerals such as zinc and phosphorus, and B-vitamins: (niacin, vitamin B12, thiamin and riboflavin). Red meat is a source of lipoic acid. Red meat contains small amounts of vitamin D. Offal such as liver contains much higher quantities than other parts of the animal.
=== President of the Royal Society === One of the most prestigious institutions in the UK was the Royal Society. Mellanby put Florey's name forward for membership in 1937, but at that time it accepted only twenty new members each year. He was elected a fellow in 1941. The Royal Society was governed by a council of twenty-one fellows, and Florey served on the council from 1942 to 1943, and again from 1951 to 1953, when he was vice president. He received the Royal Society's Royal Medal in 1951 and its Copley Medal in 1957. By custom, the president of the Royal Society served for five years, and the position alternated between the mathematical and physical sciences, and the biological sciences, so Florey was eligible in 1960. Since the president was a public figure, his private life had to be beyond reproach, which was a sore point due to his relationship with Margaret Jennings.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.